Peptides Similar to Bimagrumab
Compare Bimagrumab with related peptides and alternatives
📌TL;DR
- •4 similar peptides identified
- •Follistatin: undefined
- •GDF-8 (Myostatin): undefined
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Bimagrumab (current) | - | - |
| Follistatin | ||
| GDF-8 (Myostatin) | ||
| Trevogrumab | ||
| Apitegromab |
Overview#
Bimagrumab operates within the myostatin/activin signaling pathway, which is targeted by several therapeutic approaches at different points. Understanding the landscape of myostatin pathway modulators helps contextualize bimagrumab's unique position and comparative advantages.
Myostatin Pathway Modulators#
Point of Intervention Comparison#
| Therapy | Target | Specificity | Clinical Stage |
|---|---|---|---|
| Bimagrumab | ActRIIA/ActRIIB (receptor) | Broad (multiple ligands) | Phase 2 |
| Trevogrumab (REGN1033) | Myostatin (ligand) | Selective | Phase 2 |
| Apitegromab (SRK-015) | Latent myostatin (activation) | Selective | Phase 2/3 (SMA) |
| Follistatin | Myostatin/activin (neutralization) | Moderate | Preclinical/Gene therapy |
| ACE-031 (ramatercept) | ActRIIB-Fc trap | Broad | Discontinued |
Bimagrumab vs Trevogrumab#
| Feature | Bimagrumab | Trevogrumab (REGN1033) |
|---|---|---|
| Developer | Novartis/Versanis/Lilly | Regeneron |
| Target | ActRIIA/ActRIIB receptors | Myostatin (GDF-8) directly |
| Ligand blockade | Myostatin + activin A + GDF-11 | Myostatin only |
| Administration | IV infusion | SC injection |
| GLP-1 combination | BELIEVE (semaglutide) | Trevi trial (with GLP-1s) |
| Fat loss effect | Significant (20.5% in Phase 2) | Less characterized |
| Muscle effects | Lean mass gain + fat loss | Lean mass preservation |
Bimagrumab's broader receptor-level blockade may explain its simultaneous fat loss and lean mass effects, while trevogrumab's selective myostatin targeting may have a different side effect profile.
Bimagrumab vs Apitegromab#
| Feature | Bimagrumab | Apitegromab (SRK-015) |
|---|---|---|
| Developer | Novartis/Versanis/Lilly | Scholar Rock |
| Target | ActRII receptors | Latent myostatin (proform) |
| Mechanism | Receptor blockade | Prevents myostatin activation |
| Primary indication | Obesity/body composition | Spinal muscular atrophy |
| Administration | IV infusion | IV infusion |
| Clinical stage | Phase 2 (obesity) | Phase 2/3 (SMA) |
Apitegromab and bimagrumab target different disease contexts, with apitegromab focused on neuromuscular disease and bimagrumab repositioned toward metabolic disease.
Bimagrumab vs Follistatin#
| Feature | Bimagrumab | Follistatin |
|---|---|---|
| Type | Monoclonal antibody (145 kDa) | Natural glycoprotein (~38 kDa) |
| Mechanism | Receptor blockade | Direct ligand neutralization |
| Administration | IV infusion | Gene therapy approaches under study |
| Clinical data | Phase 2 RCTs | Limited clinical data |
| Availability | Clinical trials only | Gene therapy/research |
| Half-life | ~19 days | Short (hours for protein form) |
Bimagrumab vs ACE-031#
ACE-031 (ramatercept) was an ActRIIB-Fc fusion protein (soluble receptor trap) that was discontinued due to safety concerns including nosebleeds, gum bleeding, and telangiectasias. Bimagrumab has a different molecular format (full antibody vs Fc fusion) and blocks both ActRIIA and ActRIIB rather than ActRIIB alone.
GLP-1 Combination Landscape#
A critical competitive dynamic is the use of myostatin pathway modulators in combination with GLP-1 receptor agonists:
| Combination | Trial | Status |
|---|---|---|
| Bimagrumab + semaglutide | BELIEVE | Phase 2b completed |
| Bimagrumab + tirzepatide | NCT (Lilly) | Terminated (T2D), ongoing (obesity) |
| Trevogrumab + semaglutide/tirzepatide | Trevi | Phase 2 |
Key Differentiating Factors#
Advantages of Bimagrumab#
- Dual body composition effect: Only therapy showing simultaneous fat loss and lean mass gain
- Extensive clinical data: Multiple Phase 2 trials across indications
- BELIEVE data: Largest dataset for myostatin pathway + GLP-1 combination
- Metabolic benefits: HbA1c improvement beyond body composition effects
Limitations of Bimagrumab#
- IV administration: Requires clinic visits for infusion vs SC injection (trevogrumab)
- Broad receptor blockade: May have more off-target effects than selective approaches
- IBM failure: RESILIENT demonstrated that lean mass gains do not automatically improve function
- Development uncertainty: Lilly terminated one combination trial in 2025
Related Reading#
Frequently Asked Questions About Bimagrumab
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer